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Abstract
Vascular endothelial growth factor (VEGF) is an endogenous polypeptide that modulates angiogenesis in normal physiological conditions as well as in cancer. During angiogenesis, VEGF interacts with several other angiogenic factors, playing an important role in cell proliferation, differentiation, migration, cell survival, nitric oxide (NO) production, release of other growth factors and sympathetic innervation. Based on these mechanisms of action, several anti-VEGF drugs have been developed for cancer treatment.
This review discusses the physiology and interactions of VEGF, its mechanisms of action and role in modulating vascular homeostasis. It also discusses the adverse cardiovascular effects of recently developed anti-VEGF drugs for the treatment of various types of cancer. A critical appraisal of the human studies on these drugs is provided. Furthermore, putative mechanisms for the onset of hypertension, the most common adverse cardiovascular effect, are discussed. 






The vascular endothelial growth factor (VEGF) is an endothelial cell specific mitogen [1]. As the cardiovascular system is the first developing organ system [2] initial steps such as vasculogenesis [3] are vital during the neonatal stages of life. VEGF gene knockout causes devascularisation during the neonatal stage leading to embryonic death [4]. VEGF plays a critical role in physiological and pathological angiogenesis [5] both at the embryonic [6] and at the adult stage [7]. Most angiogenic factors are either directly or indirectly induced by VEGF since it is the only angiogenic factor present throughout all the stages of vascular development  ADDIN EN.CITE [8-10]. VEGF signalling regulates both angiogenesis (formation of blood vessels) and haematopoiesis (formation of blood cells) [11]. VEGF expression is increased in myeloma compared to normal tissues [12]. Moreover, an increased expression of VEGF in hypoxic conditions triggers tumour angiogenesis [13, 14]. The important role of VEGF in promoting angiogenesis and cancer progression is widely established [15].




VEGFs are polypeptide growth factors responsible for the formation and maintenance of blood vessels. The VEGF family has 7 members: VEGF-A, B, C, D, placental growth factor (PIGF), VEGF-E and svVEGF of which the first 5 types are encoded in the mammalian genome [16] (Figure 1). VEGF-E or viral VEGF is encoded by the parapox orf virus strain NZ7 whereas svVEGF is a snake venom derived VEGF [17]. VEGFs are homodimer structures with 8 conserved cysteine residues in a monomer peptide [18].
The human VEGF gene is located in chromosome 6p21.3 [19]. It has 8 exons separated by 7 introns with a coding region of approximately 14kb [20]. Alternative exon splicing of the VEGF gene results in 4 different species of VEGF: 121, 165, 189 and 206. VEGF-121 is a freely diffusible acidic polypeptide and does not bind to heparin. VEGF-189 and 206 are highly basic and completely sequestered in the extracellular matrix [21]. VEGF-165 has intermediate properties which correlate to most of the characteristic of the native VEGF gene such as basicity, heparin binding and being a homodimeric glycoprotein [21]. 
VEGF receptors
VEGF receptors include VEGFR1 (Flt-1), VEGFR2 (KDR/Flk-1) and VEGFR3 (Flt-3) [22] (Figure 1). VEGFR 1 and 2 possess a 1kb [23] and 4 kb [24] flanking region in their promoter region which are essential for endothelial specific expression. VEGFR1, also known as Fms like tyrosine-1 (Flt-1), is expressed in 2 forms of mRNA; one is encoded for VEGFR1 and the other is encoded for soluble Fms like tyrosine-1 (sFlt-1) [25]. The VEGF-receptor binding results in activation of a cascade of events and pathways leading to angiogenesis [26]. VEGF-A binds to VEGFR1 and 2 to regulate proliferation, migration, and survival of vascular endothelial cells [22]. VEGF-C and D bind to VEGFR3 to regulate proliferation, migration, and survival of lymphatic endothelial cells [22]. In addition, VEGF-C and D bind to VEGFR-2 but their effects on vascular endothelial cells have not yet been studied. VEGF-A is the most studied protein and is an important component responsible for vasculogenesis from progenitor cells [4]. VEGF-A/VEGFR2 binding increases vascular permeability [27]. VEGF-B binds only to VEGFR1, its functional activity being 10-fold weaker than VEGF-A [16]. Deletion of the second domain in VEGFR1 results in abolition of VEGF-VEGFR2 binding [26]. It could be speculated that VEGFR1 presents VEGF to VEGFR2 during physiological and pathological conditions. The down production of VEGFR1 mRNA would result in decreased presentation of VEGF to VEGFR2, thereby reducing angiogenic activity. In contrast, over expression of VEGFR1 mRNA results in increased VEGF-VEGFR1 binding instead of increased presentation of VEGF to VEGFR2. Thus, VEGFR1 modulates VEGF biological activity by affecting its availability to VEGFR2 for further signal transduction. This is supported by the postulation that sFlt-1 can be used as a potent inhibitor of VEGF-mediated angiogenesis in tumour cells [28]. 
VEGF co-receptors
In addition to tyrosine kinase receptors, VEGF binds to heparin [1], neuropilin-1 [29] and neuropilin-2 [30]. Neuropilin-1 and 2 (Nrp-1 and 2) are specific receptors for semaphorin [31]. Semaphorin is responsible for neuronal proliferation [32]. 
Soluble Flt-1 or sVEGFR1
Soluble Flt-1 or sVEGFR1 is a spliced soluble form of VEGFR-1 that acts as an inhibitor of VEGF activity [33]. It blocks the angiogenic action by sequestering to VEGF or heterodimerising with the extracellular binding region of the VEGFR1 and 2 (Flt-1 and Flk-1/KDR) receptors [34]. This in turn blocks the availability of receptor for phosphorylation and further signal transduction pathways mediating angiogenesis  ADDIN EN.CITE [33-36]. The difference between VEGFR1 and sFlt-1 is that the sFlt-1 receptor lacks both the transmembrane domain and the entire intracellular tyrosine kinase containing region both of which are present in the Flt-1 receptor [37]. Although both receptors have the same specificity and affinity towards VEGF sFlt-1 cannot induce signal transduction due to the structural differences described above [33]. VEGFR1 negatively modulates angiogenesis in the early stages of embryogenesis. This indicates that the physiological role of both Flt-1 and sFlt-1 is to act as a ‘decoy receptor’. 

VEGF and major angiogenic factors
In 1968, it was shown that angiogenesis is induced by several tumour-released growth factors [38]. The major factors regulating angiogenesis and their functions are described in Table 1 [16]. 
VEGF and angiopoietin-1 and 2 are important angiogenic factors involved in the physiological regulation of vascular endothelial cells [39] (Table 1). Angiopoietin-1 [40] and angiopoietin-2 [41] are pro-angiogenic and anti-angiogenic factors, respectively. The complementary action of VEGF and angiopoietin-1 are essential for blood vessel growth. Angiopoietin-1 induces resistance to plasma leakage to ensure cell integrity [42]. On the other hand, angiopoietin-2 counteracts the maturation of endothelial cells by inhibiting the action of angiopoietin-1. Notably angiopoietin-2 has also been shown to exert pro-angiogenic effects depending on the concentration of VEGF [43]. This provides insights into the dose-dependent activity of some angiogenic factors in regulating vascular physiology.
VEGF-A increases platelet derived growth factor-B (PDGF-B) expression whereas fibroblast growth factor (FGF) increases platelet derived growth factor receptor-β  (PDGFR-β) expression [44]. Pepper et al showed that VEGF-A and PDGF-B have synergistic effects in promoting neo-angiogenesis [45] (Table 1). Kano et al demonstrated that this activity occurs through PDGF-B/PDGFR-β signalling [44]. Neuropilin 1 and 2 are indirect angiogenic factors that induce endothelial cell migration and sprouting through VEGF [46] (Table 1). Matrix metalloproteinase plays an important role in tumour angiogenesis [47] with specific transcriptional up regulation of VEGF-A through Src tyrosine kinase activity [48] (Table 1). VEGF induces tissue-type and urokinase-type plasminogen activator and its inhibitor in a dose-dependent manner in microvascular endothelial cells. This relates to the balance of protease and its inhibitors during capillary morphogenesis [49] (Table 1). Thus, VEGF maintains the required protease balance enabling angiogenesis. VEGF signalling also increases delta-like ligand 4 (DII4) and notch expression while acting upstream in determining the specification of arterial vessels [50] (Table 1). 
VEGF interactions with other vascular factors 
VEGF and their receptors induce, and are induced, by several factors and signalling mechanisms to enable endothelial cell proliferation and to maintain vascular haemostasis. Most of their cellular functions are performed through VEGFR2 binding (Tables 2 and 3; Figure 2). This triggers the PI3-AKT pathway, a critical mediator of oncogenic signalling [51].
During hypoxic conditions, the hypoxia-inducing factor alpha (HIF-α) protein induces the translocation of transcriptional factors from the cytoplasm into the nucleus [52]. This results in the release of growth factors such as cytokines [53], interleukins [54] and VEGF through NF-κB activation [54]. This pathway takes place in a cyclic manner  ADDIN EN.CITE [52-55] (Figure 2 and Table 2). Endothelin is another vascular factor involved in the regulation of VEGF expression to maintain vascular tone [56] (Table 2). Angiotensin-II regulates VEGF through the renin-angiotensin system (RAS) induced NF-κB pathway which results in formation of endothelial cell substrate in the extracellular matrix (Table 2) [57]. 
VEGF forms an endothelial substrate of fibrin gel by induction of tissue type plasminogen activator, resulting in the sprouting of blood vessels in the endothelium  ADDIN EN.CITE [5, 58] (Table 3). Further, it causes leakage of plasma proteins by exerting vasodilating effects through the induction of the endothelial and inducible forms of nitric oxide synthase  (eNOS and iNOS) via the PI3-Akt pathway [59] (Table 3).  During cellular proliferation, plasma proteins are required to adhere to the endothelial substrate in the extracellular matrix. This is mediated by VEGF through the induction of adhesion factors such as vascular cellular adhesion molecule, intercellular adhesion molecule and E-selectin [60] (Table 3). VEGF-VEGFR2 binding mediates phosphorylation of focal adhesion kinase (FAK) to enhance cellular migration via the heat shock protein 90 (HSP90) which maintains the signalling stability and function of FAK  ADDIN EN.CITE [61, 62] (Table 3). It also activates paxillin along with FAK phosphorylation which recruits stress induced actin anchoring proteins thereby resulting in VEGF-induced actin reorganisation  ADDIN EN.CITE [61, 63]. Reorganisation of dendritic actin has been demonstrated during cellular migration and invasion [64]. VEGF-induced actin reorganisation improves cellular migration in endothelial cells through FAK/paxillin activation [63].
Guanylate cyclase plays a vital role in vasodilation  ADDIN EN.CITE [65, 66] by mediating cGMP synthesis [67]. Simultaneous nitric oxide (NO) production and increased cGMP levels regulate vascular tone [68]. MAPK activation is involved in the NO/cGMP cascade [69] which is responsible for VEGF-induced endothelial cell proliferation [70] (Figure 2). VEGF activates phospholipase through the MAPK pathway to initiate prostacyclin synthesis [71]. It also induces vascular permeability via NO and prostacyclin [72]. Therefore it is possible that the vasoactive effects of VEGF are at least partly coordinated by prostacyclin and NO in an MAPK activated pathway. This is supported by the fact that a stable prostacyclin analogue stimulates angiogenesis by initiating neovascularisation during wound healing [73]. Angiogenic factors are required for capillaries to sprout and organise into a microvascular network on the fibrin clot of a wound [74]. VEGF induces angiogenic action by recruiting bone marrow derived cells to accelerate tissue repair  ADDIN EN.CITE [73, 75]. Requirement of angiogenesis during wound healing support the important physiological role of VEGF in the process. Prostaglandin I2, also known as prostacyclin, is another important vasodilator that interacts with VEGF in physiological and pathological conditions [76, 77]. 

VEGF and vascular homeostasis
The cardiovascular system is the first organ system to develop and attain a functioning state in an embryo [2]. Vascularisation is an important process in the development of such system through the recruitment of endothelial progenitor cells (EPC). This is mediated by VEGF/VEGFR1 [78] and VEGF/VEGFR2 [79] signalling [80]. VEGF has mitogenic effects specifically on vascular endothelial cells [5]. It increases the survival capability of cultured endothelial cells in absence of serum in the culture medium [81]. VEGF triggers the PI3 kinase - AKT pathway through which it increases the expression of anti-apoptotic proteins [82]. This action of VEGF inhibits apoptosis and acts as a survival factor for endothelial cells. Endothelial cell function is pivotal for maintaining vascular homeostasis [83]. 
Under physiological circumstances, vascular haemostasis is a balance between several vasoconstricting and vasodilating factors. An imbalance between vasoconstriction and vasodilation leads to disturbance in the maintenance of vascular tone, vessel function and structure, and facilitates vascular disease states such as hypertension, atherosclerosis and heart failure [83]. Endothelin is a potent vasoconstrictor derived from endothelial cells [84]. VEGF has inhibitory effects on endothelin in vascular endothelial cells and, in turn, endothelin has inhibitory effects on VEGF in vascular smooth muscle cells [56]. Since NO specifically inhibits endothelin, VEGF inhibition of endothelin could be regulated through VEGF induced NO production. As a result, endothelin interacts with VEGF to maintain the homeostasis of vascular endothelial cells and vascular tone. 

Effects of VEGF on the vasculature 
VEGF-VEGFR2 binding induces vasorelaxation by increasing phospholipase C, protein kinase C and inositol 1,4,5 triphosphate activity, decreasing intracellular calcium ions and increasing synthesis/release of endothelial nitric oxide (NO) [85]. Reduction in intracellular concentration of calcium ions and increase in NO synthesis are vital steps involved in vasodilation [86]. Higher NO levels respond to VEGF-induced hypotension by reducing the expression of eNOS [87]. This is likely to be mediated by NO [68] itself and by prostaglandin I2 [88] through VEGFR2 signalling [78].
Pre-eclampsia, a condition characterised by endothelial dysfunction, hypertension and proteinuria involves higher serum levels of sFlt-1 or sVEGFR1 [89]. Higher concentrations of sFlt-1 or sVEGFR1 lead to decreased VEGF availability to VEGFR2 thus resulting in endothelial dysfunction [89]. In addition to maintaining endothelial cell integrity, renal VEGF mRNA expression increases in response to hypertension, stress and increased RAS activity. This is thought to represent a renoprotective effect [90]. During arterial injury, up-regulation of VEGF facilitates the re-endothelialisation of arterial walls [91] by mediating PKC activation of NO synthesis [92]. The NO secreted from regenerated endothelium attenuates VEGF expression in a concentration dependent manner by inhibiting the binding of PKC initiated transcription factor (activator protein-1) to the VEGF promoter region [92]. This concept of reciprocal activity between VEGF and NO indicate their significant role in the maintenance of endothelial cell integrity.
In ischaemic cardiomyopathy with co-existing hypoxia, VEGF mRNA expression is up regulated with an increase in vascular density [93]. This is likely to occur through induction of HIF-α. In such conditions, VEGF increases microvascular permeability by inducing leakage of plasma proteins. Acute topical administration of VEGF results in fenestrated endothelial cells and increased vascular permeability [94]. Exaggerated vasorelaxation could be a response to endothelial and renal dysfunction which impairs baroreceptor function and decreases VEGF clearance in hypertensive rats [95]. The accumulation of VEGF secondary to impaired renal clearance in hypertensive rats could possibly have a pronounced effect on the exaggerated vasorelaxation.
By binding to receptor-1, VEGF initiates vascular sympathetic innervation by improving the growth of sympathetic axons [96]. VEGF also inhibits semaphorin/Nrp binding and prevents semaphorin-induced collapse of sympathetic nerves [97]. Semaphorin/Nrp binding aids in vascular embryonic development [98] by increasing the affinity of VEGF-A to VEGFR2 and thereby enhancing downstream signal transduction [29]. There is no evidence that semaphorin and/or neuropilin independently induce signal transduction after VEGF binding. Neuropilin aids in presenting VEGF to its receptor thereby increasing VEGF activity but does not independently initiate angiogenesis [99]. Vascular sympathetic innervation is an important mediator of blood pressure and blood flow [100]. Thus, VEGF maintains vascular haemostasis by mediating the physiological balance of autonomic and cardiovascular systems in addition to maintaining vascular sympathetic innervation (Figure 3).

Rationale for anti-angiogenesis in cancer treatment 
Judah Folkman proposed anti-angiogenic therapy to inhibit the growth of solid tumours before the discovery of VEGF [101]. Agents with potential anti-angiogenic effects include endothelial cell proliferation inhibitors (growth factors and their receptors), vascular targeted agents (micro vessel disrupting agents) and anti-hypoxic agents (VEGF expression is increased in hypoxic conditions) [102]. Endothelial cell proliferation inhibitors mainly include agents inhibiting VEGF. VEGF is known to induce angiogenic response in tumour models [103, 104]. As previously described, VEGF interacts with most angiogenic factors. VEGF is also demonstrated to be present throughout the tumour life cycle [105]. Therefore, inhibition of VEGF as an anti-angiogenic therapy could prove effective in cancer treatment.

Anti-VEGF drugs
At present, 3 anti-VEGF drugs are used in the treatment of cancer:  bevacizumab, sorafenib and sunitinib. All 3 drugs have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of specific types of cancer. These drugs inhibit VEGF signalling either by blocking the VEGF ligand or the VEGF receptor. Bevacizumab is a humanised monoclonal antibody that selectively binds to VEGF and specifically blocks the VEGF ligand and signal reception [106]. It was the first systemically used VEGF inhibitor approved by the FDA. It is currently approved in combination with irinotecan, fluorouracil and leucovorin (IFL) as first- or second-line treatment of metastatic carcinoma of the colon or rectum. Sunitinib and sorafenib are orally administered, small molecule inhibitors of multiple receptor tyrosine kinases used in the treatment of tumour progression. Sunitinib inhibits VEGF receptors (VEGFR-1, 2, 3), platelet derived growth factor receptors (PDGFR-a and b), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1, and glial cell-derived neurotrophic factor receptor. It is approved for advanced renal cell carcinoma and gastrointestinal stromal tumours (GIST) [9]. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-b, RAF kinase, FLT3, KIT, p38 MAP kinase (p38-alpha, MAPK14). It is approved for treatment in advanced renal cell carcinoma and is in phase III clinical trials for hepatocellular carcinoma, metastatic melanoma, and non small cell lung cancer  ADDIN EN.CITE [107].
There are several other anti-VEGF drugs which are currently under different clinical phases: 
1.	GW786034B (pazopanib), a tyrosine kinase inhibitor, targets VEGFR1, 2 and 3. It is under phase III trial for renal cell cancer [108].
2.	AZD2171, a tyrosine kinase inhibitor, targets VEGFR1, 2, 3, PDGFRβ and C-KIT. It is under phase I trial in combination therapy with carboplatin and paclitaxel for advanced non small cell lung cancer [109].
3.	PTK787/ZK222584 (vatalanib), a tyrosine kinase inhibitor, targets VEGFR1, 2, 3, PDGFRβ and C-KIT [110]. It is under phase I trial in combination with cetuximab for advanced solid tumours [111].
4.	VEGF trap is a decoy receptor which targets VEGF-A and B [112]. It is under phase I trial for advanced solid tumours [113].
5.	ZD6474, a tyrosine kinase inhibitor, targets VEGFR2, EGFR, FGFR1 and RET [114]. It is under phase I trial for nasopharyngeal carcinoma [115].
6.	AMG-706, a tyrosine kinase inhibitor, targets VEGFR1, 2 and 3, PDGFR1 and KIT, a cytokine receptor expressed in haematopoietic stem cells [116]. It is under phase Ib trial in combination with carboplatin/paclitaxel and/or panitumumab for advanced non-small cell lung cancer [117].
7.	AG013736,  a tyrosine kinase inhibitor, targets VEGFR1, 2, 3 and PDGFR [118]. It is under phase I study in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumours [119].

Effects of VEGF inhibition on cardiovascular homeostasis
Hypertension
Anti-VEGF drugs inhibit endothelial cell proliferation by targeting endothelial mitogens, their receptors, endothelial integrins and matrix metalloproteinases. This process leads to an impairment of endothelial function, which in turn negatively affects cardiovascular homeostasis [120]. Hypertension is the most frequently observed and documented side effect of VEGF blocking in clinical trials with an estimated incidence of 32% [121]. Anti-VEGF drugs could also reduce NO synthesis. This might further contribute to the vasoconstriction, which in turn leads to increased peripheral resistance and blood pressure. 
VEGF expression levels depend on the type of hypertension. For example, VEGF expression has been shown to be reduced during intrauterine hypertension [122]. By contrast, a study comparing VEGF mRNA expression in hypoxia induced (HI) vs. carcinogen induced (CI) pulmonary hypertension showed increased VEGF levels in the former and decreased VEGF levels in the latter [123]. VEGF expression is increased in venous hypertensive conditions [124]. VEGF might convert venous hypertension into intracellular signals for angiogenic activity [125]. Studies by Swendsen et al showed higher sVEGFR1 concentrations in arteries vs. veins in rectal cancer patients [126]. The anti-VEGF drugs currently used might be specific for the arterial system. This hypothesis warrants further studies where VEGF expression levels, signalling and structural morphology in arteries and veins are studied simultaneously.
The incidence of arterial hypertension in clinical trials with anti-VEGF drugs ranges between 0.2% and 72% (Table 4). Grade 3/4 hypertension (> 180/110 mmHg) was reported in most studies with a wide range of follow-up during treatment (1-33 months) (Table 4). 
Notably, the development of hypertension was more frequently observed with certain anti-VEGF drugs such as sunitinib (5-56%), sorafenib (1-34%), AZD2171 (22-72%), AMG-706 (20-49%) and AG-013736 (6-61%), all of which inhibit PDGFR, than with others (bevacizumab: 0.2-34%, ZD6474: 0.2-12%) (Table 4). PDGFR signalling helps in recruitment of de novo VEGF from stromal fibroblasts in VEGF–null cells  ADDIN EN.CITE [127]. Therefore, it is not surprising that PDGFR inhibition leads to an increased disturbance of vascular homeostasis, which might explain at least partly the increased incidence of hypertension with specific anti-VEGF drugs (Table 4).
Some studies have shown that the addition of platinum containing compounds to bevacizumab treatment was associated with a lower incidence of hypertension (4.0% vs. 6.8%)  ADDIN EN.CITE [128, 129]. Platinum containing compounds act through activation of the MAPK pathway which regulates cell proliferation, differentiation, survival and apoptosis [130]. Cisplatin activates the MAPK members, ERK (extracellular signal regulated kinase) and SAPK (stress activated protein kinase, p38 kinase), following its exposure to tumour cells [131]. This might explain the decreased incidence of hypertension when platinum containing compounds are co-administered with bevacizumab [132]. However, further studies are required to confirm these findings.
Infused 5-fluorouracil with bevacizumab was associated with a reduced incidence of hypertension (5%) compared with bolus dosing (22.4%)  ADDIN EN.CITE [121, 133]. Drugs administered by intravenous bolus are rapidly cleared from the circulation, hence a relatively short plasma half-life, whereas infusional dosing provides a sustained drug release [134]. Since there is a sustained release, the total drug intensity and cumulative dose will be higher in infusional administration compared with bolus administration. 5-fluorouracil has been shown to damage endothelial cells and lead to thrombus formation [135]. Following the 5-fluorouracil induced endothelial injury there is an increased release and leakage of vasodilatory and anti-coagulant substances [136]. Only when this mechanism gets exhausted, pro-coagulant factors facilitate thrombus formation [136]. In the above studies the incidence of thrombotic events was 19.4% with bolus administration [121] vs. 18% with infusional dosing [133]. Considering the higher cumulative dose and the similar incidence of thrombotic events it could be speculated that when 5-fluorouracil is infused the release of vasodilatory and anti-coagulant substances is not exhausted rapidly. This might explain the reduced incidence of hypertension with infusional dosing of 5-flourouracil.
The clinical studies on bevacizumab have demonstrated a relatively low incidence of hypertension in specific types of cancer. For example, studies on lung cancer showed a 6.8% [128], 16.6% [132], 17.7%[137] and 16.1% [138] incidence of hypertension whereas studies on gastric cancer showed a 4% [129] incidence of hypertension. Anti-VEGF drugs specifically target VEGF which is an endothelial cell specific protein [139]. The lung [140] and gastric [141] tissues are primarily lined with epithelial cells. Therefore, these tissues would have a reduced amount of VEGF proteins compared to those primarily lined with endothelial cells, hence the reduced susceptibility to pro-hypertensive effects. The development of hypertension regardless of tissue type could be secondary to circulating endothelial cells (CEC), an increased levels of which have been documented in different types of cancer [142]. CEC expression levels might be related with anti-VEGF drug-induced hypertension as there is 1) a significant correlation between CEC and plasma VEGF levels [143] and 2) an increased CEC expression in cancer [143]. [144]. CEC levels and kinetics might help in stratifying the clinical benefit provided by anti-angiogenic treatment [145]. [146]. Gene expression profiling showed varied CEC levels in different types of cancer [147]. Therefore, it could be hypothesised that the extent of anti-VEGF drug-induced hypertension depends also on VEGF inhibition in CEC.
Genetic factors might play an important role in the inter-individual differences in the risk of developing hypertension during anti-VEGF treatment as well as in treatment efficacy. A recent study has demonstrated that a particular VEGF genotype is associated with an increased incidence of hypertension in patients with metastatic renal cell carcinoma undertaking anti-VEGF treatment [148]. A phase III study demonstrated an association between hypertension and certain VEGF genotypes [149]. VEGF has a number of isoforms namely VEGF121 [20], VEGF145 [150], VEGF165 [103], VEGF183 [151], VEGF189 [152], and VEGF206 [153] which are formed by exon splicing at different regions. Further studies on each of the isoforms are warranted to clarify the association between VEGF polymorphism and risk of hypertension with anti-VEGF drugs.
There is evidence that bevacizumab-induced hypertension is associated with better tumour response. For example, Scartozzi et al demonstrated that patients with colorectal cancer developing hypertension with bevacizumab had an increased progression free survival (14.5 months) when compared with patients who did not develop hypertension (3.1 months) [154]. Therefore, the development of hypertension could be used as marker of anti-VEGF drug efficacy [146]. 
Due to the recent introduction of anti-VEGF drugs in clinical practice and the relatively short survival of patients receiving them it is not possible to establish the long-term impact of newly developed or worsened hypertension on cardiovascular outcomes. Moreover, due to short half life of anti-VEGF drugs, their toxicities can be reverted to a certain extent with the termination of treatment [155]. This hypothesis is supported by recent studies demonstrating the rapid disappearance of capillary rarefaction following termination of VEGF inhibition [156]. The proposed molecular pathway in this context is the following: anti-VEGF drugs inhibit the PI3/Akt/PKB pathway, which is activated by VEGF/VEGFR2 binding [51], thereby decreasing the induction of anti-apoptotic proteins [81]. This would result in decreased tumour cell survival. VEGF also induces cell proliferation by activating membrane associated GTPase through the Ras/MAPK pathway [157], which is inhibited by anti-VEGF drugs. On the other hand, angiotensin-II also induces the MAPK pathway [158]. Studies by Kishi et al showed that Ras protein levels and the Ras/MAPK/ERK½ pathway are both up regulated in hypertensive rats [159]. In addition, G-protein coupled receptor (GPCR) and Focal Adhesion Kinase (FAK) activate the Ras/MAPK pathway [160] through the Kinase Suppressor of Ras (KSR). The KSR-induced Ras/MAPK activation is shown to: 1) inhibit the PKB pathway in ceramide treated cells [161] which would further prevent anti-apoptotic protein induction, thereby leading to increased cell death; 2) initiate the c-Raf-1/MEK-1 pathway which dephosphorylates BAD proteins [161]. The BAD protein is a pro-apoptotic member of the Bcl-2 family. Its apoptotic effects are enhanced by heterodimerisation with Bcl-xL [162] and inhibited by its phosphorylation [163]; 3) activate endothelial angiotensin-II through NFκB [164]. Ras activation of endothelial angiotensin-II contributes to the development of angiotensin-II dependent hypertension [165] by up regulation of Elk-1 transcription factors [166] (Figure 4). The above studies suggest that the Ras/Raf/MAPK/ERK pathway is pro-hypertensive  ADDIN EN.CITE [157-160, 164, 165]. 
As discussed earlier, PDGF recruits de novo VEGF from stromal fibroblasts in VEGF–null cells  ADDIN EN.CITE [127]. Currently used drugs targeting the Ras pathway inhibit VEGF as well as PDGF  ADDIN EN.CITE [9, 107]. Anti-VEGF drugs would therefore inhibit the VEGF-induced Ras pathway. This in turn would prevent PDGF-induced de novo VEGF which might increase per se the incidence of hypertension. On the other hand, the Ras/MAPK pathway is also initiated by other factors such as GPCR, FAK and angiotensin-II which causes hypertension. In addition, Ras acts as an intermediatory protein linking PDGF receptor to FAK [167], which is involved in mechanical signalling of hypertension [168]. We propose that the Ras pathway is pro-hypertensive regardless of anti-VEGF treatment (angiotensin-II initiation). However, this effect is augmented during anti-VEGF treatment (inhibition of PDGF-induced de novo VEGF + angiotensin-II initiation).
Proteinuria
Another common untoward cardiovascular effect during anti-VEGF treatment is proteinuria. The incidence of proteinuria with bevacizumab is 23-38% in patients with colorectal cancer and up to 64% in patients with renal cell carcinoma [169]. The development of proteinuria and hypertension often coexist in the same patient. Proposed mechanisms responsible for the development of anti-VEGF induced proteinuria include a) hypertension-mediated glomerular damage [90]; b) reduced VEGF expression by podocytes which adversely affects renal function with loss of endothelial fenestrations in glomerular capillaries, proliferation of glomerular endothelial cells, and loss of podocyte function  ADDIN EN.CITE [170, 171]; and c) pathological changes in glomerular architecture resembling those observed in eclampsia [172]. 
There is overwhelming evidence that proteinuria significantly increases cardiovascular risk [173]. However, similarly to hypertension, the clinical impact of this complication in cancer patients receiving treatment with anti-VEGF remains to be established.   Moreover, proteinuria occurring during anti-VEGF therapy is usually mild and temporary as it usually resolves upon treatment discontinuation.  
Thrombosis and haemorrhage
Thrombosis and haemorrhage are other less frequently reported adverse events. The reported incidence of thrombotic events during bevacizumab treatment plus chemotherapy was 4% vs. 2% with chemotherapy alone [174]. Mild haemorrhagic events during treatment with sunitinib occurred in 26% of patients whereas more severe bleeding events occurred in 9% of patients [128]. 
As previously discussed, VEGF induces the synthesis of anti-apoptotic proteins [81]. Therefore, anti-VEGF drugs could trigger a pro-apoptotic state with consequent endothelial cell injury [175]. This would expose extracellular matrix (ECM), collagen, and von Willebrand factor (vWF) to circulating platelets, resulting in coagulation and thrombus formation [176] (Figure 5). ADAMTS, a metalloproteinase induced by VEGF, cleaves vWF [177, 178]. Therefore, anti-VEGF drugs might lead to increased vWF expression, thus escalating thrombus formation. Other putative mechanisms to explain the increased risk of thrombosis include reduced synthesis of NO and prostacyclin and increased blood haematocrit and blood viscosity secondary to overproduction of the hormone erythropoietin [179].   
On the other hand, VEGF also induces tissue factor (TF) [180], an initiator of blood coagulation [181]. Again, we could extrapolate that anti-VEGF drugs inhibit TF thereby exerting anti-coagulant effects leading to haemorrhage. The lack of the previously discussed effects of VEGF on vascular and endothelial cell integrity might also contribute to the increased risk of haemorrhage. 
The increased incidence of thrombosis and bleeding during anti-VEGF treatment highlights once again the multiplicity of actions of VEGF on the vasculature. 
Cardiac dysfunction
The untoward cardiac effects of anti-VEGF drugs primarily include heart failure with left ventricular dysfunction, QT prolongation, and myocardial injury  ADDIN EN.CITE [182-185]. The incidence of cardiac dysfunction ranges between 2-7% in patients treated with trastuzumab [186], 2.2-3% with bevacizumab  ADDIN EN.CITE [187, 188], and 4-11% with sunitinib [185]. The available evidence suggests that the increase in blood pressure secondary to anti-VEGF treatment results in increased cardiac afterload, reduction of capillary density in the myocardium, global contractile dysfunction and heart failure  ADDIN EN.CITE [189, 190]. 

Assessing the incidence of new-onset hypertension with anti-VEGF drugs - methodological issues 
The results of oncology studies assessing the incidence of newly-developed hypertension during anti-VEGF treatment must be interpreted with caution for several reasons. First, the rapid temporal changes in blood pressure could not be clearly established due to the relative long time interval between assessment visits in most oncology trials [191]. A cohort study by Azizi et al showed an early and progressive blood pressure elevation in 100% of patients undergoing weekly self-measurements at home [192].  Second, several patients treated with anti-VEGF drugs had a previous nephrectomy. This increases per se the risk of developing hypertension for several reasons, including hypervolaemia [192] [193]. Therefore, the development of hypertension in such patients should be analysed separately.
A third issue is related to the discrepancies in the definition of hypertension between different professional societies. This might lead to inappropriate conclusions. For example, a rise in blood pressure by 10 mmHg from any initial range is considered as hypertension according to the ESH (European Society of Hypertension) definition. However, it is considered as Grade 0 toxicity according to the NCI-CTC (National Cancer Institute – Common toxicity criteria) definition if the increase is still within the specified normal range [191]. Since hypertension is considered as a surrogate marker of anti-VEGF treatment efficacy [146] considering blood pressure as a continuous, rather than dichotomous, variable would help to overcome some of these methodological concerns [191]. Clearly, more research is warranted.

Further putative mechanisms of anti-VEGF drug-induced hypertension
As previously discussed, VEGF exerts significant vasodilatory effects  ADDIN EN.CITE [78, 194]. The direct inhibition of VEGF action should cause vasoconstriction resulting in increased blood pressure. Interestingly, however, only a proportion of anti-VEGF drug treated patients develop hypertension. Moreover, in those patients developing hypertension a significant inter-individual variability in hypertension severity is observed. Whilst existing co-morbidities and the co-administration of other cancer drugs might affect the risk of developing hypertension, as discussed before, other pathways involved in vascular homeostasis and blood pressure control might interact with the effects of VEGF and its blockade. The role of these pathways is herewith discussed. 
Haemodynamics
The anti-VEGF drug-mediated impairment in endothelial function would favour peripheral arterial vasoconstriction, hence an increase in peripheral vascular resistance [106]. The effects of an increase in peripheral vascular resistance on systemic blood pressure are dependent on the elastic properties of the arterial wall, e.g. arterial compliance  ADDIN EN.CITE [195, 196]. There is good evidence that endothelial function tonically modulates arterial compliance as impaired endothelial function significantly reduces arterial compliance, through NO-dependent mechanisms [197]. A reduced arterial compliance, also described as increased arterial stiffness, reduces the ‘buffering’ capacity of the arterial tree, in particular the large arteries, during systole. This leads to a progressive increase in systolic blood pressure without significant changes, or sometimes a reduction, in diastolic blood pressure [195] (Figure 6). The susceptibility of an individual patient to anti-VEGF drug induced hypertension might depend on a number of factors affecting arterial compliance. These include genetic predisposition, co-existing cardiovascular risk factors and concomitant treatment with several vasoactive drugs  ADDIN EN.CITE [198-200]. Since VEGF regulates vascular tone, anti-VEGF drugs could affect vascular tone to cause changes in arterial compliance which in turn directly affects large arteries, small arteries and arterioles [201]. Microvascular rarefaction is one of the vascular dysfunctions associated with hypertension [202]. Steeghs et al in 2008 demonstrated that telatinib, an anti-VEGF drug during its phase I trial showed significant reduction in capillary density and skin blood flux which could be due to an increased rarefaction concurrent with the development of hypertension [203].
Baroreceptors
Baroreceptors are sensory mechano-receptors present in blood vessels [204]. They are located in the following sites: 1) aortic arch at the origins of the brachiocephalic artery, the left subclavian artery, and the Botallo’s duct; 2) brachiocephalic artery at its bifurcation into the right subclavian and the right common carotid artery; 3) carotid sinuses; 4) carotid arteries at the origin of the superior thyroid artery  ADDIN EN.CITE [205-207]. These receptors are sensitive to changes in blood pressure and act by initiating or inhibiting the vasomotor centres located in the brainstem in order to maintain blood pressure values within a physiological range [205]. They send neuronal messages to the rostral ventrolateral medulla (RVLM) during alterations in blood pressure which is reflected back by exerting modulatory effects on both the parasympathetic and the sympathetic nervous system [208]. Anti-VEGF drugs could impair baroreceptor function by preventing their sensitivity to blood pressure changes (Figure 7). This might be secondary to the impairment of endothelial function caused by such drugs, which would in turn lead to carotid artery stiffening and reduced baroreceptor sensitivity [209]. Although anti-VEGF drug induced baroreceptor impairment could also be a potential mechanism causing hypertension the factors affecting arterial compliance described above could again account for inter-individual differences in both the development and the severity of hypertension. 
Cellular factors
VEGFR2 signalling is predominantly responsible for the angiogenic activity of VEGF. As previously discussed, the binding of VEGF to VEGFR2 triggers the PI3-AKT pathway [51]. The key downstream function of PI3K activation is phosphorylation and regulation of its targets such as GSK3 (Glycogen Synthase Kinase 3), IRS-1 (insulin receptor susbtrate-1), PDE-3B (phosphodiesterase-3B), BAD protein, human caspase 9, Forkhead and NF-kB transcription factors, mTOR, eNOS, Raf protein kinase, BRCA1 and p21Cip1 /WAF1  ADDIN EN.CITE [210-215]. The inhibition of the PI3-AKT pathway leads to decreased iNOS and cGMP production [216] which is ought to occur during anti-VEGF treatment. Decreased cGMP production is due to decreased availability of guanylate cyclase, the enzyme converting GTP to cGMP [67]. eNOS is activated through AKT phosphorylation [217]. Therefore, AKT inhibition by anti-VEGF treatment could also decrease eNOS expression and activity. Moreover, cGMP is a gate for sodium ions [218]. The decreased production of cGMP would lead to a reduced number of available sodium gates in endothelial cells. Retention of sodium ions in the blood stream would lead to hypertonicity with increased blood volume and increased blood pressure. 
For similar reasons, patients undertaking chemotherapy drugs also targeting sodium channels would possibly have an increased incidence of hypertension when co-administered with anti-VEGF drugs. Other examples of drugs acting on sodium channels are listed below:
1.	Alkaloids  ADDIN EN.CITE [219-221]
2.	Local Anaesthetics [222]
3.	Class I anti-arrhythmic agents [223]
4.	Anticonvulsants [224]
Glomerular endothelial cells require VEGF expression to maintain their normal physiological structure and function under both normotensive and hypertensive states [90]. This is inhibited by anti-VEGF drugs, thereby causing an alteration in blood pressure. The co-factors tetrahydrobiopterin [225] and calmodulin [226] modulate eNOS activity by facilitating NOS dimer formation leading to NO synthesis and further blood pressure control. Drugs affecting these factors could also alter blood pressure control  ADDIN EN.CITE [227-230].

Conclusions




Table 1: Angiogenic Factors
Angiogenic factors	Functions
Angiopoietin-1	Maturation of newly formed vesselsSuppression of vascular leakageInhibition of inflammationPromotion of structural integrity of adult vasculature and prevention of endothelial cell death
Angiopoitein-2	Angiopoietin-1 antagonistBalances vascular regression and cell maturation
Placenta derived growth factor (PDGF-B) and receptor beta (PDGFR-β)	Promotes neo-angiogenesis through PDGF-B/PDGFR-β signalling
Fibroblast growth factor	Stimulation of proliferation and differentiationInduces PDGFR-β
Vascular endothelial growth factor (VEGF)	Modulation of vascular permeability
VEGF receptor, neuropilin-1 and 2 co-receptors	Induction of signal transduction
Matrix metalloproteinase	Sprouting of capillaries
Plasminogen activator	Conversion of plasminogen to plasmin with fibrinolysisPromotion of remodelling processes such as proteolysis in extracellular matrix aiding angiogenesis
Plasminogen activator inhibitor	Maintenance of a scaffold required for endothelial cell migration by protecting the cell membrane from plasmin-mediated proteolysis
Delta notch	Development of endothelial cells on matrigelSprouting of functional blood vessels
Ephrin EphB4	Arterio-venous differentiation
Cadherin, integrin	Cell adhesionFibrin- or collagen-induced capillary formation
Netrin, Semaphorin	Axon guidance for neuron proliferation
Delta-like ligand 4 (DII4) 	Negative feedback regulator of angiogenic sprouting

Table 2: VEGF activating factors
VEGF inducing factors	Mechanism of induction	Physiological/pathological context
Cytokines (interleukins and other growth factors)	Cytokines are induced by hypoxic conditions through NF kB pathway by VEGF/VEGFR2 binding [53]. 	The promoter region of IL-6 contains the NF kB binding site. This initiates the physiological/pathological functions of cytokines in hypoxic conditions to induce the release of interleukin hormones and other growth factors [54].
Hypoxia Inducing Factor-alpha	HIF expression is activated through the PI3–AKT–mTOR pathway by VEGF/VEGFR2 binding 	Normoxia promotes hydroxylation of HIF1-alpha at proline residue to proteolyse it by the VHL gene [231]. Decrease in oxygen stabilises HIF protein which then initiates its own physiological function. HIF1-β and CBP/p300 bind with hypoxia response element (HRE) to increase the transcriptional activity of growth factors, which is responsible for increase in VEGF mRNA expression during low oxygen tension [52].
Angiotensin II	Angiotensin regulates VEGF expression through RAS (renin angiotensin system) induced NF-κB pathway in stromal fibroblasts [57] by VEGF/VEGFR2 binding. 	Angiotensin II regulation of VEGF expression results in the formation of collagen in the extracellular matrix which in turn is the substrate for the formation of endothelial cells. The VEGF promoter region contains the binding site for AP-1 and NF-κB [152].
Matrix metalloproteinase	Activated by Src tyrosine kinase activity [48].	Specific transcriptional up regulation of VEGF-A in tumour angiogenesis [47]. 
NF-κB pathway	Activated by VEGF/VEGFR2/p38MAPK-MKK2 signalling [232].  	NF-kappa B promotes the expression of VEGF and iNOS [55].




Table 3: VEGF activated factors
VEGF induced factors	Mechanism of action	Physiological/Pathological context
Endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS)	Activated by VEGF/VEGFR2 binding through PI3-AKT pathway [59].	NOS catalyses the formation of NO in endothelial cells to maintain vascular haemostasis.
Vascular cellular adhesion molecule (VCAM), intercellular adhesion molecule (ICAM) and E-selectin	Activated via Nuclear Factor-κB activation by VEGF/VEGFR2 binding specifically dependent upon PI3 kinase [60].	Adhesion factors involved during endothelial cell proliferation.
Tissue type plasminogen activator (PA), plasminogen activator inhibitor (PAI) and collagenase [58]	Activated via ERK1/2 pathway by VEGF/VEGFR1 binding [234].	Formation of fibrin gel in the extravascular region which is a substrate for the formation of new blood vessels on the endothelial cell layer. VEGF balances the extracellular proteolysis during endothelial cell morphogenesis. This facilitates the migration and sprouting of blood vessels in endothelial cells [5]. 
Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) [235]	Activated via protein kinase C dependent pathway [236]	Important cell signalling process during cell invasion and cellular remodelling, affecting vascular morphogenesis [237].
Focal adhesion kinase	Activated by VEGF-VEGFR2 binding [61].	Enhances cellular migration via HSP90  ADDIN EN.CITE [61, 62].
Hexose transport and tissue factor (TF) [238]	Hexose transport is performed by VEGF-VEGFR2 activation of PKC-β which mediates the translocation of cytosolic GLUT-1 to plasma membrane surface [239].TF activation by VEGF is mediated by EGR-1, a transcription factor [180].Both factors are activated by VEGF/VEGFR2 binding	During mitosis and inflammation, cells require increased glucose metabolism to transform their nonthrombogenic surface to a procoagulant surface. This transformation is performed by a tissue factor (TF) which is induced by VEGF and TNF [240] as a result of a cellular response in order to maintain vascular haemostasis during cell proliferation [238].





Table 4: Clinical trials on anti-VEGF drugs and development/worsening of hypertension 
Ref.	Study information	Name and dose of anti-VEGF drug	Additional drug(s)	Cancer type	Age (years)	No. of pts	Duration of the study (months)	Development of hypertension
[241]	Phase I/II dose escalation trial	Bevacizumab - escalating doses ranging from 3 mg/kg to 20 mg/kg	-	Metastatic breast cancer	29-78	75	5	Hypertension: 22%
[242]	Phase II study	Bevacizumab 10 mg/kg	Docetaxel	Metastatic Breast cancer	39-68	27	1-15 (median 6)	Grade 2 hypertension: 15%, grade 3 hypertension: 4%
[243]	Randomized, double-blind, phase II trial	Bevacizumab - 3 and 10 mg/kg	-	Metastatic renal cancer	53.5 (median)	76	27	Hypertension: 1 pt (3mg/kg), 14 pts (10 mg/kg)
[128]	Randomized phase II study	Bevacizumab - 7.5 and 15 mg/kg	Paclitaxel, Carboplatin	Non-small cell lung cancer	≥65	417	33	Grade 3 hypertension: 6.8%, grade 4 hypertension: 0.2%
[132]	Randomized phase II trial	Bevacizumab - 7.5 and 15 mg/kg	Paclitaxel, Carboplatin	Metastatic non-small cell lung cancer	≥18	67	3	All grades hypertension: 16.6%
[129]	Phase II study	Bevacizumab - 7.5 mg/kg	Docetaxel, Oxaliplatin	Gastric and gastroesphageal junction cancer	57 (median)	23	-	Grade 3/4 hypertension: 4%
[244]	Randomized phase II trial	Bevacizumab - 5 mg/kg and 10 mg/kg	Fluorouracil Leucovorin	Metastatic colorectal cancer	≥18	68	12	All grades hypertension: 11% (5mg), 28% (10 mg); Grade 3/4 hypertension: 3% (5mg), 8% (10mg)
[137]	Multicenter, randomized phase II trial 	Bevacizumab - 15 mg/kg	Erlotinib, (Docetaxel or pemetrexed)	Non small cell lung cancer	40-88	79	13	All grades hypertension: 17.7%
[187]	Open label, randomized phase III clinical trial	Bevacizumab - 10mg/kg	Paclitaxel	Metastatic breast cancer	29-84	365	26	Grade 3 hypertension: 14.5%, grade 4 hypertension: 0.3%
[188]	Randomized phase III trial	Bevacizumab - 15 mg/kg	Capecitabine	Metastatic breast cancer	29-78	232	26	All grades hypertension: 17.9%
[245]	Randomized phase III trial	Bevacizumab - 7.5 mg/kg	Capecitabine, Oxaliplatin Cetuximab	Advanced colorectal cancer	31-83	389	6.8	Grade 3/4 hypertension: 5%
[246]	Multicenter, randomized, double-blind, phase III trial	Bevacizumab - 10 mg/kg	Interferon-2 alpha	Metastatic renal cell carcinoma	18-82	327	13.3	Hypertension: 3%
[247]	Randomized phase III trial	Bevacizumab - 10 mg/kg	Oxaliplatin Leucovorin Fluorouracil	Metastatic colorectal cancer	23-85	529	5	Grade 3 hypertension: 7.3%
[121]	Randomized phase III trial	Bevacizumab - 5 mg/kg 	Irinotecan Leucovorin Fluorouracil	Metastatic colorectal cancer	59.5 (mean)	402	10	All grades hypertension: 22.4%, grade 3/4 hypertension: 11%
[248]	Randomized phase III trial	Bevacizumab - 5 mg/kg	Fluorouracil Leucovorin	Metastatic colorectal cancer	59.7 (mean)	110	24	All grades hypertension: 33.9%, grade 3/4 hypertension: 18.3%
[133]	International, multicenter, open-label, phase IV trial	Bevacizumab - 5 mg/kg	Infusional Fluorouracil, Leucovorin Irinotecan	Metastatic colorectal cancer	31-82	150	9	Hypertension: 5%
[138]	Phase I study	Sorafenib - 200 and 400 mg	Gefitinib	Refractory or recurrent non-small cell lung cancer	46-78	31	1 - 12 (median 3)	All grades hypertension: 16.1%, grade 3 hypertension: 3.2%
[249]	Phase I study	Sorafenib - 400 mg	Erlotinib	Advanced solid tumours	30-77	17	10	All grades hypertension: 34%
[250]	Phase I study	Sorafenib - 400 mg	Gemcitabine	Advanced solid tumours	39-83	42	2-15 (median  4)	All grades hypertension: 7.1%
[251]	Open-label phase II study	Sorafenib - 400 mg	-	Metastatic, iodine-refractory thyroid carcinoma	31-89	36	5	Grade 3 hypertension: 8%
[252]	Open label, single arm phase II study	Sorafenib - 400 mg	-	Androgen independent prostate cancer	50-77	22	1	Grade 1 hypertension: 4 pts, grade 2 hypertension: 3 pts, grade 3 hypertension: 1 pt
[253]	Phase II study	Sorafenib - 400 mg	-	Hormone refractory prostate cancer	52-82	55	3	Grade 3 hypertension: 6%
[254]	Phase II study	Sorafenib - 400 mg	-	Advanced thyroid cancer	31-89	30	7	Grade 1/2 hypertension: 30%, grade 3/4 hypertension: 13%
[255]	Phase II study	Sorafenib - 400 mg	-	Advanced renal cell carcinoma	-	131	6	All grades Hypertension - 27.5%, Grade 3/4 hypertension - 12.2%
[256]	Phase II study	Sorafenib - 400 mg	-	Metastatic castration resistant prostate cancer	49-85	24	2-12 (median 2.5)	Grade 2 hypertension: 12.5%
[257]	Phase II study	Sorafenib - 400 mg	-	Advanced hepatocellular carcinoma	28-79	51	2.5-16 (median  3)	Grade 1/2 hypertension: 14%, grade 3 hypertension: 8%
[258]	Phase II study	Sorafenib - 400 mg	Interferon alpha 2B	Metastatic renal cell cancer	33-81	40	2-17 (median 6)	Grade 1/2 hypertension: 10%
[259]	Phase II study	Sorafenib – 400 mg and Axitinib – 5 mg	-	Metastatic renal cell carcinoma	-	62	17.5	All grades hypertension: 16.1%
[260]	Phase III study	Sorafenib - 400 mg	-	Advanced renal cell carcinoma	 -	451	4.5	Grade 3 hypertension: 3%
[261]	Phase I study	Sunitinib - 25, 37.5 and 50 mg Bevacizumab - 10 mg/kg 	-	Metastatic renal cell carcinoma	57 (median)	25	7.5 (median)	Grade 3/4 hypertension: 56%
[262]	Phase II study	Sunitinib - 50 mg	-	Metastatic colorectal cancer	30-78	82	2.5	All grades hypertension: 18.3%; grade 3/4 hypertension: 6.1%
[263]	Multicenter, Phase II study	Sunitinib - 50 mg	-	Advanced non-small cell lung cancer	33-86	63	13.5	All grades hypertension: 11%; grade 3 hypertension: 5%
[264]	Phase II, open-label, multicenter study	Sunitinib - 50 mg	-	Metastatic breast cancer	36-70	64	1-12 (median 3)	All grades hypertension: 16%; grade 3 hypertension: 6%
[265]	Phase II study	Sunitinib - 50 mg	-	Refractory thyroid cancer	58 (median)	43	3	All grades hypertension: 42%; grade 3/4 hypertension: 16%
[266]	Phase II study	Sunitinib - 50 mg	 -	Recurrent and/or metastatic squamous cell carcinoma of the head and neck	59 (median)	22	2.5	Grade 3/4 hypertension: 22.7%
[267]	Multicenter, randomized, phase III trial	Sunitinib - 50 mg	Interferon alfa	Metastatic renal cell carcinoma	27-87	375	1-15 (median 6)	All grades hypertension: 24%; grade 3 hypertension: 8%
[268]	Phase I dose escalation and pharmacokinetic study	AZD2171 - Escalating doses 1, 2.5, 5, 10, 20, 30 mg	-	Hormone refractory prostate cancer	50-90	26	 -	All grades hypertension: 31%
[269]	Phase I study	AZD2171 - 20, 30 and 40 mg	-	Advanced solid tumours	19-78	83	3	All grades hypertension: 29%
[270]	Phase II study	AZD2171 - 45 mg	-	Recurrent or persistent ovarian, peritoneal or fallopian tube cancer	31-87	49	1-9 (median 3)	All grades hypertension: 72%; grade 3 hypertension: 33%
[271]	Phase II study	AZD2171 - 45 mg	-	Advanced metastatic renal cell carcinoma	44-80	23	4 week cycle	All grades hypertension: 50%; grade 3 hypertension: 21.7%
[272]	Phase I dose escalation trial	VEGF trap (Aflibercept) - 4 mg/kg (20 pts) and 6 mg/kg (12 pts)	Gemcitabine	Advanced solid tumours	38-75	32	1-9 (median 2)	Grade 3 hypertension: 22%
[273]	Double-blind, placebo-controlled, multi-center phase II trial	VEGF trap (Aflibercept) - 4 mg/kg	-	Metastatic ovarian cancer	-	55	-	Grade 3/4 hypertension: 7%
[274]	Phase II trial	VEGF trap (Aflibercept) - 4 mg/kg	-	Metastatic colorectal cancer	39-80	51	3 (median)	All grades hypertension: 54.9%; grade 3 hypertension: 7.8%
[275]	Phase II trial	VEGF trap (Aflibercept) - 4 mg/kg	-	Recurrent or metastatic gynaecologic soft tissue sarcoma	 -	25	2-28 (median 4)	Grade 3 hypertension: 18%
[276]	Phase I study	AG-013736 - 5 to 30 mg	 -	Advanced solid tumours	41-76	36	28 day cycle	All grades hypertension: 61%; grade 3 hypertension: 30%
[277]	Phase I study	AG-013736 - 5 mg	Gemcitabine	Advanced pancreatic cancer	-	8	0.7-4.5 (median 2.2)	Grade 2 hypertension: 37.5%
[278]	Phase II study	AG-013736 - 5 mg	 -	Acute myeloid leukemia or myelodysplastic syndrome	58-88	12	0.03-6 (median  2.7)	Grade 3/4 hypertension: 25%
[279]	Phase II study	AG-013736 - 5 mg	 -	Advanced non-small cell lung cancer	39-80	32	3	Grade 3/4 hypertension: 6%
[280]	Phase II study	AG-013736 - 5 mg	 -	Advanced thyroid cancer	26-84	60	0.2-12	All grades hypertension: 20%
[281]	Two centre, phase I, open label, sequential dose escalation study	AMG-706 - 50 to 175 mg	 -	Advanced solid tumours	25-90	71	1	All grades hypertension: 42%; grade 3 hypertension: 20%
[282]	Multicenter, open label, phase II, single arm study	AMG-706 - 125 mg	 -	Differentiated thyroid cancer	36-81	93	3.5	All grades hypertension: 49%; grade 3 hypertension: 22%
[283]	Phase I dose escalation trial	ZD6474 - 50, 100, 200, 300, 500, 600mg 	 -	Solid malignant tumour	28-82	77	2.5	Grade 3 hypertension: 2% vs. 0% vs. 1% vs. 0% vs. 1% vs. 4%
[284]	Multicentre Phase II trial	ZD6474 - 100 and 300 mg	 -	Metastatic breast cancer	32-81	46	1.5	Grade 1 hypertension in 300 mg group: 2.4%
[285]	Open label phase II study	ZD6474 - 300mg	 -	Hereditary metastatic medullary thyroid cancer	22-77	16	0.5-12.5 (median  4.5)	Grade 3 hypertension: 12.5%







Figure 1: VEGF and its receptors




Figure 2: VEGF/VEGFR2 signal transductions
VEGF and its signal transductions with VEGFR2 binding. PI3K – Phosphoinositol 3 kinase; PKB – Protein kinase B; mTOR – Mammalian target of Rapamycin; S6K – S6 protein kinase; eIF4E1 - Eukaryotic Translation Initiation Factor 4E1; HIF1 α – Hypoxia inducing factor 1α; HIF1 β – Hypoxia inducing factor 1β; ARNT – Aryl hydrocarbon receptor nuclear translocator; P300 - ; CREB – cAMP response element binding; JAB1 – Jun activation domain binding; cJUN – Cellular JUN; HRE – Hypoxia response elements; NF-κB – Nuclear Factor Kappa B; NO – Nitric oxide; NOS – Nitric oxide synthase; ERK – Extracellular signal regulated kinase; PLC – Phospholipase C; PKC – Protein kinase C; ADAMTS – A disintegrin and metalloproteinase with thrombospondin motifs; IP3 – Inositol triphosphate; SHC – Src homology 2 Domain containing; RAS – Renin Angiotensin system; MKK2 – Mitogen activated protein kinase kinase 2; MAPK – Mitogen activated protein kinase; PA – Plasminogen activator; PAI – Plasminogen activator inhibitor; MEK – MAPK/ERK kinase; VCAM – Vascular cellular adhesion molecule; ICAM – Intercellular adhesion molecule.












Figure 5: Anti-VEGF drugs and thrombosis
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